[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369850-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369850-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","therapeutic-targeting-of-syndecan-1-axis-overcomes-acquired-resistance-to-kras-targeted-therapy-in-gastrointestinal-cancers","Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers","","Therapeutic KRAS* inhibitors show limited durability due to rapid resistance. This article dissects how acquired resistance develops and identifies intervention points to overcome it in gastrointestinal cancers. Using pancreatic and colorectal cancer models, it shows that surface SDC1 falls after KRAS* inhibition but rebounds in cells that escape KRAS* dependence. Mechanistic evidence links YAP1 activation to SDC1 surface relocalization, driving macropinocytosis nutrient salvaging and multiple RTK signaling to sustain tumors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/therapeutic-targeting-of-syndecan-1-axis-overcomes-acquired-resistance-to-kras-targeted-therapy-in-gastrointestinal-cancers/369850/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/therapeutic-targeting-of-syndecan-1-axis-overcomes-acquired-resistance-to-kras-targeted-therapy-in-gastrointestinal-cancers/369850.png","ImageObject",300,407,{"name":42,"@type":43},"4398046744996","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What causes acquired resistance to KRAS*-targeted therapy?","Question",{"text":63,"@type":64},"The study attributes resistance to KRAS*-inhibited tumor cells that bypass KRAS* dependency, enabling recovery of surface SDC1 and downstream pro-survival signaling pathways.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does YAP1 influence syndecan-1 (SDC1) after KRAS* inhibition?",{"text":68,"@type":64},"YAP1 activation drives the recovery of surface SDC1 localization following KRAS* inhibition, restoring SDC1 at the tumor cell surface.",{"name":70,"@type":61,"acceptedAnswer":71},"Why does restored surface SDC1 promote resistance?",{"text":72,"@type":64},"Surface SDC1 supports macropinocytosis-mediated nutrient salvaging and activates multiple receptor tyrosine kinases, which together maintain tumor growth under KRAS*-targeted pressure.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369850,1790839014,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":11,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":138,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":99,"preview_page_count":33,"preview_urls":144},4398046744996,"Article  \nTherapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers  \nGraphical abstract  \nHighlights  \n• YAP1 drives surface SDC1 recovery following KRAS* inhibition  \n• Surface SDC1 sustains macropinocytosis and activates RTKs to promote resistance  \n• Therapeutic targeting of the YAP1-SDC1 axis overcomes resistance in preclinical models  \nAuthors  \nMadelaine S. Theardy,  \nMitsunobu Takeda, Alexey Sorokin, ..., Haoqiang Ying, Scott Kopetz, Wantong Yao  \nCorrespondence  \n[mtakeda@gesurg.med.osaka-u.ac.jp](mtakeda@gesurg.med.osaka-u.ac.jp)[ ](mtakeda@gesurg.med.osaka-u.ac.jp)(M.T.),  \n[hying@mdanderson.org](hying@mdanderson.org) (H.Y.),  \n[skopetz@mdanderson.org](skopetz@mdanderson.org) (S.K.),  \n[wyao22@mdanderson.org](wyao22@mdanderson.org) (W.Y.)  \nIn brief  \nOvercoming resistance to  \nKRAS*-targeted therapy remains a major challenge. Theardy et al. demonstrate that YAP1 drives the recovery of surface SDC1 upon KRAS* inhibition by downregulating ARF6 GAPs, thereby activating RTKs and macropinocytosis to promote resistance. Targeting the YAP1-SDC1 axis represents a promising strategy to combat resistance in KRAS*-driven cancers.  \nTheardy et al., 2025, Cell Reports Medicine 6, 102253  \nAugust 19, 2025 © 2025 The Authors. Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2025.102253](https://doi.org/10.1016/j.xcrm.2025.102253)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nTherapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers  \nMadelaine S. Theardy,1,2,11 Mitsunobu Takeda,3,4,11,* Alexey Sorokin,5,11 Shuaitong Chen,1,2 Zecheng Yang,1,2 Xiaofei Wang,1 Preeti Kanikarla,5 Oluwadara Coker,2,5 Phuoc Nguyen,2,6 Yongkun Wei,6 Jun Yao,6 Liang Yan,6 Yanqing Jin,1 Yiming Cai,2,6 Masakatsu Paku,1,4 Ziheng Chen,3 Kara Z. Li,1 Francesca Citron,3 Hideo Tomihara,3,4  \nSisi Gao,3 Angela K. Deem,3 Jun Zhao,7 Huamin Wang,1,7 Samir Hanash,2,8 Ronald A. DePinho,2,9 Anirban Maitra,1,2,7,10 Giulio F. Draetta,2,3 Haoqiang Ying,2,6,* Scott Kopetz,2,5,* and Wantong Yao1,2,6,12,*  \n1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA  \n2The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA  \n3Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA  \n4Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Osaka, Japan  \n5Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA  \n6Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA  \n7Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA  \n8Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, TX, USA  \n9Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA  \n10Sheikh Ahmed Center for Pancreatic Cancer Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA  \n11These authors contributed equally  \n12Lead contact  \n*[Correspondence:](Correspondence: mtakeda@gesurg.med.osaka-u.ac.jp)[ mtakeda@gesurg.med.osaka-u.ac.jp](Correspondence: mtakeda@gesurg.med.osaka-u.ac.jp) (M.T.), [hying@mdanderson.org](hying@mdanderson.org) (H.Y.), [skopetz@mdanderson.org](skopetz@mdanderson.org) (S. K.), [wyao22@mdanderson.org](wyao22@mdanderson.org) (W.Y.)  \n[https://doi.org/10.1016/j.xcrm.2025.102253](https://doi.org/10.1016/j.xcrm.2025.102253)  \nSUMMARY  \nThe therapeutic benefit of recently developed mutant KRAS (KRAS*) inhibitors remains limited by the rapid onset of resistance. Here, we aim to delineate mechanisms underlying acquired resistance and identify actionable targets for overcoming this clinical challenge. P","cbCaihLgIH56Hi8J","https://ap.wps.com/l/cbCaihLgIH56Hi8J","pdf",16903325,24,"English","# Graphical abstract\n# Highlights\n# In brief\n# Summary\n# Introduction","[{\"question\":\"What causes acquired resistance to KRAS*-targeted therapy?\",\"answer\":\"The study attributes resistance to KRAS*-inhibited tumor cells that bypass KRAS* dependency, enabling recovery of surface SDC1 and downstream pro-survival signaling pathways.\"},{\"question\":\"How does YAP1 influence syndecan-1 (SDC1) after KRAS* inhibition?\",\"answer\":\"YAP1 activation drives the recovery of surface SDC1 localization following KRAS* inhibition, restoring SDC1 at the tumor cell surface.\"},{\"question\":\"Why does restored surface SDC1 promote resistance?\",\"answer\":\"Surface SDC1 supports macropinocytosis-mediated nutrient salvaging and activates multiple receptor tyrosine kinases, which together maintain tumor growth under KRAS*-targeted pressure.\"}]","Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers | PDF",1790184856,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d5eb91552dfc9f68a339af9a54b7823.webp",983,1276,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e91b454983499d19c514f1b97e5ba975.webp",982,1275,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eacce034d6cf83ff7fddb8435ce14de9.webp",981,1273,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e7fa7aef63afe4688dc795ef66a45a7.webp",980,1272]